In last trading session, Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) saw 1.79 million shares changing hands with its beta currently measuring 2.22. Company’s recent per share price level of $24.33 trading at $0.25 or 1.04% at ring of the bell on the day assigns it a market valuation of $1.19B. That closing price of RYTM’s stock is at a discount of -27.33% from its 52-week high price of $30.98 and is indicating a premium of 87.51% from its 52-week low price of $3.04. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.45 million shares which gives us an average trading volume of 2.50 million if we extend that period to 3-months.
For Rhythm Pharmaceuticals Inc. (RYTM), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 1.90. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.95 in the current quarter.
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) trade information
Upright in the green during last session for gaining 1.04%, in the last five days RYTM remained trading in the red while hitting it’s week-highest on Thursday, 09/15/22 when the stock touched $24.33 price level, adding 14.63% to its value on the day. Rhythm Pharmaceuticals Inc.’s shares saw a change of 143.79% in year-to-date performance and have moved -21.13% in past 5-day. Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) showed a performance of 3.22% in past 30-days. Number of shares sold short was 5.94 million shares which calculate 1.82 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $29.25 to the stock, which implies a rise of 16.82% to its current value. Analysts have been projecting $16.00 as a low price target for the stock while placing it at a high target of $40.00. It follows that stock’s current price would drop -64.41% in reaching the projected high whereas dropping to the targeted low would mean a gain of 34.24% for stock’s current value.
Rhythm Pharmaceuticals Inc. (RYTM) estimates and forecasts
Statistics highlight that Rhythm Pharmaceuticals Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 110.10% of value to its shares in past 6 months, showing an annual growth rate of -172.86% while that of industry is 1.70. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -35.70% in the current quarter and calculating -45.70% decrease in the next quarter. This year revenue growth is estimated to rise 672.40% from the last financial year’s standing.
8 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $2.58 million for the same. And 8 analysts are in estimates of company making revenue of $4.78 million in the next quarter that will end on Sep 2022. Company posted $274k and $930k of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 841.60% while estimating it to be 414.00% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -4.40% during past 5 years. In 2022, company’s earnings growth rate is likely to be around 53.80% while estimates for its earnings growth in next 5 years are of -9.00%.
Rhythm Pharmaceuticals Inc. is more likely to be releasing its next quarterly report in October and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM)’s Major holders
Insiders are in possession of 0.32% of company’s total shares while institution are holding 85.11 percent of that, with stock having share float percentage of 85.38%. Investors also watch the number of corporate investors in a company very closely, which is 85.11% institutions for Rhythm Pharmaceuticals Inc. that are currently holding shares of the company. Primecap Management Company is the top institutional holder at RYTM for having 6.36 million shares of worth $154.84 million. And as of Jun 29, 2022, it was holding 12.50% of the company’s outstanding shares.
The second largest institutional holder is NEA Management Company, LLC, which was holding about 4.91 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 9.65% of outstanding shares, having a total worth of $119.52 million.
On the other hand, Primecap Odyssey Aggressive Growth Fund and Federated Hermes Kaufmann Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 4.79 million shares of worth $116.62 million or 9.41% of the total outstanding shares. The later fund manager was in possession of 3.95 million shares on Apr 29, 2022, making its stake of worth around $96.15 million in the company or a holder of 7.76% of company’s stock.